9c99946058
- Source: inbox/queue/2026-04-25-glp1-oud-phase2-trial-protocol-ncta06548490-ascpjournal-2025.md - Domain: health - Claims: 0, Entities: 0 - Enrichments: 1 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
67 lines
3.6 KiB
Markdown
67 lines
3.6 KiB
Markdown
---
|
|
type: source
|
|
title: "Semaglutide for OUD Phase 2 Trial Protocol Published (Addiction Science & Clinical Practice, 2025)"
|
|
author: "Grigson PS et al. (Penn State / NIH)"
|
|
url: https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-025-00618-2
|
|
date: 2025-05-01
|
|
domain: health
|
|
secondary_domains: []
|
|
format: trial-protocol
|
|
status: processed
|
|
processed_by: vida
|
|
processed_date: 2026-04-25
|
|
priority: low
|
|
tags: [GLP-1, semaglutide, OUD, opioid-use-disorder, clinical-trial, addiction, reward-circuit, VTA-dopamine]
|
|
extraction_model: "anthropic/claude-sonnet-4.5"
|
|
---
|
|
|
|
## Content
|
|
|
|
Published in Addiction Science & Clinical Practice (BioMed Central). PMID 40502777 (very high PMID — published mid-2025).
|
|
|
|
**Trial: NCT06548490**
|
|
- Phase 2, double-blind, placebo-controlled RCT
|
|
- Principal investigator: Grigson PS (Penn State)
|
|
- n = 200 participants
|
|
- Population: Treatment-refractory OUD — patients already enrolled in MOUD (buprenorphine or methadone) programs who continue using illicit opioids
|
|
- Sites: 3 US sites
|
|
- Enrollment status: First participant enrolled January 27, 2025; sites fully open June 2025
|
|
- Expected completion: November 2026
|
|
|
|
**Primary endpoint:**
|
|
Opioid abstinence measured by urine drug screens and self-report over 12 weeks
|
|
|
|
**Rationale:**
|
|
- Observational studies show GLP-1 RAs associated with lower opioid overdose risk
|
|
- Animal models: GLP-1 RAs reduce opioid self-administration
|
|
- Qeadan 2025 (Addiction journal): 40% lower overdose rate (IRR 0.60) in real-world cohort
|
|
- Mechanism: shared VTA dopamine reward circuit with metabolic/alcohol applications
|
|
- Semaglutide is the agent being tested
|
|
|
|
**Gap this fills:**
|
|
No completed Phase 2 RCT for GLP-1 + OUD as of April 2026. This is the definitive human trial that will either confirm or refute the animal/observational signal.
|
|
|
|
## Agent Notes
|
|
|
|
**Why this matters:** Status update on the thread from Session 26-27. The protocol is published and the trial is actively enrolling (first participant January 2025). November 2026 completion means results available late 2026 / early 2027 at the earliest (analysis takes time after completion).
|
|
|
|
**What surprised me:** Nothing new here — this confirms the information from Sessions 26-27. The protocol is now formally published (not just registered), which adds credibility to the research program but doesn't change the evidence status.
|
|
|
|
**What I expected but didn't find:** Results. The trial is still running. No interim analysis published.
|
|
|
|
**KB connections:**
|
|
- Directly extends: Sessions 26-27 GLP-1 reward circuit thread
|
|
- Connects to: GLP-1 receptor agonists are the largest therapeutic category launch... — OUD application would significantly extend the therapeutic scope
|
|
- If results are positive, would extend the "shared VTA dopamine mechanism" claim from AUD to OUD
|
|
- Potentially relevant to addiction epidemiology / deaths of despair claims
|
|
|
|
**Extraction hints:**
|
|
- Update existing queue entry if one exists (none found — this is new)
|
|
- The protocol publication is evidence that the research is active and properly registered — raises credibility of the overall OUD signal
|
|
- Do NOT extract a claim from the protocol itself — extract only from results when published
|
|
- FLAG for monitoring: November 2026 completion → results likely Q1-Q2 2027
|
|
|
|
## Curator Notes (structured handoff for extractor)
|
|
PRIMARY CONNECTION: GLP-1 reward circuit thread (Session 26-27 musing candidates)
|
|
WHY ARCHIVED: Status update on the definitive OUD trial. Confirms enrollment active, timeline (November 2026 completion). No results yet.
|
|
EXTRACTION HINT: No claim extraction from protocol. Monitor for results in late 2026/early 2027. Flag as a session monitoring thread — revisit when results publish.
|